| Literature DB >> 29320397 |
Xu Zhang1, Liansheng Qiao2, Yankun Chen3, Bowen Zhao4, Yu Gu5, Xiaoqian Huo6, Yanling Zhang7, Gongyu Li8.
Abstract
The metabotropic glutamate receptors (mGluRs) are known as both synaptic receptors and taste receptors. This feature is highly similar to the Property and Flavor theory of Traditional Chinese medicine (TCM), which has the pharmacological effect and flavor. In this study, six ligand based pharmacophore (LBP) models, seven homology modeling models, and fourteen molecular docking models of mGluRs were built based on orthosteric and allosteric sites to screening potential compounds from Traditional Chinese Medicine Database (TCMD). Based on the Pharmacopoeia of the People's Republic of China, TCMs of compounds and their flavors were traced and listed. According to the tracing result, we found that the TCMs of the compounds which bound to orthosteric sites of mGluRs are highly correlated to a sweet flavor, while the allosteric site corresponds to a bitter flavor. Meanwhile, the pharmacological effects of TCMs with highly frequent flavors were further analyzed. We found that those TCMs play a neuroprotective role through the efficiencies of detumescence, promoting blood circulation, analgesic effect, and so on. This study provides a guide for developing new neuroprotective drugs from TCMs which target mGluRs. Moreover, it is the first study to present a novel approach to discuss the association relationship between flavor and the neuroprotective mechanism of TCM based on mGluRs.Entities:
Keywords: allosteric; five flavors; metabotropic glutamate receptors (mGluRs); neuroprotection; traditional Chinese medicine (TCM); virtual screening
Mesh:
Substances:
Year: 2018 PMID: 29320397 PMCID: PMC5796112 DOI: 10.3390/ijms19010163
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1The strategy of analyzing the association relationship between flavor and neuroprotection of traditional Chinese medication (TCM) based on the metabotropic glutamate receptors (mGluRs).
The result of the pharmacophore models of orthosteric antagonist of mGluR I.
| Model | Specificity | N_HITS | PARETP | Energy | Sterics | HBOND | MOL-QRY |
|---|---|---|---|---|---|---|---|
| model 01 | 3.458 | 6 | 0 | 10.79 | 203.10 | 107.90 | 2.29 |
| model 02 | 3.456 | 6 | 0 | 4.52 | 193.60 | 101.10 | 2.90 |
| model 11 | 3.458 | 6 | 0 | 14.14 | 200.50 | 108.90 | 2.29 |
| model 13 | 3.454 | 6 | 0 | 16.61 | 203.30 | 107.40 | 2.15 |
| model 15 | 3.451 | 6 | 0 | 3.73 | 187.10 | 107.70 | 0.66 |
| model 16 | 3.452 | 6 | 0 | 6.98 | 188.50 | 102.70 | 2.29 |
| model 17 | 3.452 | 6 | 0 | 8.95 | 195.10 | 99.40 | 2.29 |
| model 18 | 3.452 | 6 | 0 | 10.72 | 187.40 | 104.70 | 2.29 |
a Bold text refer to the optimal model.
The ranking results of orthosteric GALAHAD models of mGluR I.
| Model | Specificity | Energy | Sterics | HBOND | MOL-QRY | ∑Ranking |
|---|---|---|---|---|---|---|
| model 01 | 1 | 7 | 2 | 2 | 2 | 15 |
| model 02 | 4 | 2 | 6 | 8 | 1 | 22 |
| model 11 | 1 | 8 | 4 | 1 | 2 | 17 |
| model 13 | 4 | 9 | 1 | 5 | 6 | 26 |
| model 15 | 4 | 1 | 9 | 4 | 7 | 26 |
| model 16 | 7 | 3 | 7 | 7 | 2 | 27 |
| model 17 | 7 | 4 | 5 | 9 | 2 | 28 |
| model 18 | 7 | 5 | 8 | 6 | 2 | 29 |
a Bold text refer to the optimal model.
Figure 2(a) The optimal pharmacophore model of orthosteric site of mGluR I (model 03); (b) Model 03 mapped with the compound used to build model.
Figure 3(a) The optimal pharmacophore model of allosteric site of mGluR I (model 01); (b) Model 01 mapped with the compound used to build model.
The results of database search.
| Number of Compounds | Pharmacophore Screening | Drug-Like Compounds | Blood–Brain Barrier Permeability | |
|---|---|---|---|---|
| Crystal Structure | ||||
| mGluR I | Orthoteric site | 123 | 89 | 43 |
| Allosteric site | 320 | 221 | 94 | |
| mGluR II | Orthoteric site | 178 | 103 | 30 |
| Allosteric site | 532 | 287 | 105 | |
| mGluR III | Orthoteric site | 110 | 80 | 3 |
| Allosteric site | 1714 | 392 | 23 |
Selection of template proteins and evaluation of models.
| Domain | Target | Templates | Identity Value | Ramachandran Plot | ERRAT |
|---|---|---|---|---|---|
| Extracellular Domain | mGluR4 | 3MQ4 | 99% | 93.79% | 80.000 |
| mGluR8 | 3MQ4 | 72% | 94.26% | 83.559 | |
| 7TMD | mGluR2 | 4OR2 | 52% | 99.60% | 89.879 |
| mGluR3 | 4OO9 | 47% | 95.70% | 87.391 | |
| mGluR4 | 4OR2 | 43% | 98.43% | 94.400 | |
| mGluR7 | 4OO9 | 43% | 98.11% | 89.453 | |
| mGluR8 | 5CGC | 44% | 100% | 88.462 |
Figure 4The comparison between the initial binding pose (yellow) and the docked pose. (a) mGluR1; (b) mGluR2; (c) mGluR3.
The data of correlation between the rank of compounds experimental affinity (Ki) and docking score of mGluR4.
| No_Compounds | Ki | Rank of Ki | Total Score | Rank of Total Score |
|---|---|---|---|---|
| CHEMBL33567 | 910 | 1 | 7.2647 | 2 |
| CHEMBL277475 | 5200 | 2 | 7.4445 | 1 |
| CHEMBL329236 | 8800 | 3 | 6.6985 | 3 |
| CHEMBL89000 | 21,000 | 4 | 6.6781 | 4 |
| CHEMBL90501 | 23,000 | 5 | 6.1632 | 5 |
| CHEMBL88612 | 26,000 | 6 | 4.3929 | 7 |
| CHEMBL41221 | 470,000 | 7 | 5.6421 | 6 |
| Correlation | 0.9286 | |||
The data of correlation between the rank of compounds experimental affinity (Ki) and docking score of mGluR7.
| No_Compounds | Ki (nM) | Rank of Ki | Total Score | Rank of Total Score |
|---|---|---|---|---|
| CHEMBL33567 | 175,000 | 1 | 6.8675 | 1 |
| CHEMBL277475 | 185,000 | 2 | 6.4943 | 2 |
| BDBM17657 | 5,400,000 | 3 | 5.215 | 3 |
| Correlation | 1.0000 | |||
The data of correlation between the rank of compounds experimental affinity (Ki) and docking score of mGluR8.
| No_Compounds | Ki | Rank of Ki | Total Score | Rank of Total Score |
|---|---|---|---|---|
| CHEMBL33567 | 61 | 1 | 6.3650 | 2 |
| CHEMBL277475 | 210 | 2 | 6.9249 | 1 |
| CHEMBL89000 | 1700 | 3 | 6.0272 | 3 |
| CHEMBL280563 | 3400 | 4 | 5.9511 | 4 |
| CHEMBL88999 | 7300 | 5 | 5.1538 | 9 |
| BDBM17657 | 9500 | 6 | 4.6927 | 5 |
| CHEMBL8759 | 12,000 | 7 | 4.1048 | 6 |
| CHEMBL330097 | 15,000 | 8 | 3.6829 | 7 |
| CHEMBL34453 | 45,000 | 9 | 5.9186 | 8 |
| Correlation | 0.8167 | |||
Identification and evaluation of the orthosteric active pockets.
| Domian | Target | Crystal Structure | Initial Ligand | RMSD/Correlation a |
|---|---|---|---|---|
| Extracellular Domain | mGluR1 | 3KS9 | Z99 | 1.4946 Å |
| mGluR5 | 3LMK | NAG | / | |
| mGluR2 | 4XAQ | 40F | 1.1403 Å | |
| mGluR3 | 4XAR | 40F | 0.5063 Å | |
| mGluR4 | Homology Model | Z99 | 0.9286 | |
| MGluR7 | 3MQ4 | 1.0000 | ||
| MGluR8 | Homology Model | 0.8167 |
a Plain and bold text refer to RMSD and Correlation.
Figure 5(a) The mapping results of Morusimic acid D with the best pharmacophore of orhtosteric site of mGluR I; (b) the docking result of Morusimic acid D with the crystal mGluR1.
Figure 6The comparison between the initial binding pose (yellow) and the docked pose. (a) mGluR1; (b) mGluR5.
The identification and rationality of the allosteric active pocket.
| Domian | Target | Crystal Structure | Define Pocket | RMSD |
|---|---|---|---|---|
| 7TMD | mGluR1 | 4OR2 | FM9 | 1.6314 Å |
| mGluR5 | 4OO9 | 2U8 | 1.0754 Å | |
| mGluR2 | Homology Model | amino acids | / | |
| mGluR3 | Homology Model | amino acids | / | |
| mGluR4 | Homology Model | amino acids | / | |
| mGluR7 | Homology Model | amino acids | / | |
| mGluR8 | Homology Model | amino acids | / |
Figure 7(a) The mapping results of Paeoniflorigenone with the best pharmacophore of allosteric site of mGluR І; (b) the docking result of Paeoniflorigenone with the crystal structure of mGluR1.
Figure 8The sketch map of flavors, targets, and efficiencies.